EBITDA Margin % is calculated as EBITDA divided by its Revenue. GNI Group's EBITDA for the
three
months ended in Mar. 2026 was €-12.5 Mil. GNI Group's Revenue for the
three
months ended in Mar. 2026 was €30.1 Mil. Therefore, GNI Group's EBITDA margin for the quarter that ended in Mar. 2026 was -41.44%.
GNI Group (FRA:3G6) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GNI Group EBITDA Margin % Related Terms
GNI Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GNI Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3G6 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, GNI Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GNI Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GNI Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GNI Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNI Group (FRA:3G6) has a EBITDA Margin % of -41.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GNI Group and its competitors. According to the industry distribution chart, GNI Group ranks #366 out of 944 companies in the Biotechnology industry, placing it in the top 38.8%.
Is GNI Group's EBITDA Margin % too high?
GNI Group's current EBITDA Margin % is -41.44%. Based on the distribution chart, GNI Group ranks #366 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GNI Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does GNI Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #366 out of 944 companies for EBITDA Margin %. This puts GNI Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GNI Group and its competitors. GNI Group's current EBITDA Margin % is -41.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
GNI Group (FRA:3G6) has a current EBITDA Margin % of -41.44%. The stock's GF Value™ is €14.61, compared to a current price of €13.20 — trading 9.7% below its estimated fair value. The current EBITDA Margin % is -41.44%. GNI Group's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GNI Group (FRA:3G6), the current EBITDA Margin % is -41.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GNI Group (FRA:3G6) Overvalued in 2026?
Based on GuruFocus' analysis, GNI Group stock appears to be undervalued.
The current stock price of €13.20 is trading 9.7% below its estimated GF Value™ of €14.61.
Key valuation signals for FRA:3G6:
EBITDA Margin %: -41.44%
GF Value™: €14.61 vs. price of €13.20 (9.7% below fair value)
No single metric tells the full story. See the FRA:3G6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
84GF Score
Get the complete analysis for FRA:3G6
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3G6 has been successfully added to your 
